biOasis Technologies Ord Shs V.BTI.H

Chart of the day!!!!!!!!!!!!!!!! Prothena.

[narmac]

Chart of the Day: Prothena
September 2, 2021: Published by Barchart.com

---

---

The Barchart Chart of the Day belongs to the biomedical company Prothena (NASDAQ:PRTA).  I found the stock by sorting Barchart's Top 100 Stocks list first by the most frequent number of new highs in the last month then used the Flipchart feature to review the charts for consistent price appreciation.  Since the Trend Spotter signaled a buy on 8/5 the stock gained 28.58%.

 
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; A, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
 

Prothena Corporation plc

77 Sir John Rogersons QuayBlock C Grand Canal DocklandsDublin 2Ireland353 1 236 2500https://www.prothena.com
 

 
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Barchart technical indicators:

• 100% technical buy signals
• 254.22+ Weighted Alpha
• 469.97% gain in the last year
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 15 new highs and up 36.39% in the last month
• Technical support level at 70.22
• Recently traded at 71.93 with a 50 day moving average of 56.22

Fundamental factors:

• Market Cap $3.10 billion
• Revenue and Earnings are all over the charts
• Wall Street analysts issued 5 strong buy and 7 buy recommendations on the stock
• TipRanks experts rate the stock 10/10
• 4,970 investors are monitoring the stock on Seeking Alpha

The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stock are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.
 
Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PRTA, over the next 72 hours.
More on this symbol:

·         QUOTES ·         Overview ·         Performance Report   ·         CHARTS ·         Interactive Chart ·         Technical Chart   ·         TECHNICALS ·         Technical Analysis ·         Trader’s Cheat Sheet ·         Barchart Opinion ·         Trading Strategies ·         Price History

·         OPTIONS ·         Options Quotes ·         Volatility & Greeks ·         Covered Calls ·         Naked Puts ·         Option Spreads   ·         COMPANY ·         News ·         Profile ·         SEC Filings ·         Competitors ·         Stock Comparison

·         ANALYSTS ·         Earnings Estimates ·         Analyst Ratings   ·         FINANCIALS ·         Income Statement ·         Cash Flow ·         Balance Sheet   ·         ARCHIVE ·         Past Reports

[prophetoffacts]

This post has been removed in accordance with Community Policy

[JDavenport]

So, profitoffacts, fit this article into your discussion of Prothena.  Is there a case to be made that PRX012 might be, could be, an xB3 drug? Do a search on when PRX012 was first revealed? Interesting? No? How does the information in the article fit with Bioasis's very much confusing March/21 goings-on with Prothena's options extensions? Why is so low a dose of PRX012 needed